Clinical Trial Update: Pharmacogenomics Studies of Antidepressants [Phase 4]

View source ↗

Summary

A Phase 4 pharmacogenomics study update in Major Depressive Disorder. It focuses on how genetic factors influence response to Venlafaxine and Fluoxetine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Fluoxetine (Fluoxetine)
• Venlafaxine (Venlafaxine)

Snippet

Sponsor: National Cheng-Kung University Hospital | Conditions: Major Depressive Disorder, Antidepressive Agents | Phase 4 | Status: UNKNOWN